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Objective 
The effect of donor bone marrow was evaluated for its poten-
tially favorable effect in the authors' simultaneous pancreas/ 
kidney transplant program. 
Methods 
From July 1994 to January 1999, 177 pancreas transplants 
were performed, 151 of which were simultaneous pancreas! 
kidney transplants. All patients received tacrolimus, mycophe-
nolate mofetil, and steroids for immunosuppression (azathio-
prine was used in the first year of the program). Fifty-three 
simultaneous pancreas/kidney transplant recipients received 
penoperative unmodified donor bone marrow, 3 to 6 x 108 
cells/kg. 
Results 
Overall actuarial survival rates at 1 and 3 years were 98% and 
95% (patient), 95% and 87% (kidney), and 86% and 80% 
(pancreas), respectively. In the adjuvant bone marrow group, 
1- and 3-year survival rates were 96% and 91 % (patient), 
95% and 87% (kidney), and 83% and 83% (pancreas), re-
spectively. For 98 recipients who did not receive bone mar-
row, survival rates at 1 and 3 years were 100% and 98% (pa-
tient), 96% and 86% (kidney), and 87% and 79% (pancreas), 
respectively. No pancreas allografts were lost after 3 months 
Over the past 10 years. the evolution of pancreas trans-
plantation has been impressive. Outcomes are being 
achieved that match those of the other solid organ trans-
plants in terms of patient and graft survival rates. U reduc-
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in bone marrow recipients, and seven in the non-bone mar-
row recipients were lost to rejection at 0.7,6.7,8.8,14.6, 
24.1, 24.3, and 25.5 months. 
Twenty-two percent of bone marrow patients were steroid-
free at 1 year, 45% at 2 years, and 67% at 3 years. Nineteen 
percent of the non-bone marrow recipients were steroid-free 
at 1 year, 38% at 2 years, and 45% (p = 0.02) at 3 years. The 
mean acute cellular rejection rate was 0.94 ::t 1.1 in the bone 
marrow group and 1.57 ::t 1.3 (p = 0.003) in the non-bone 
marrow group (includes borderline rejection and multiple re-
jections). The level of donor cell chimerism in the peripheral 
blood of bone marrow patients was at least two logs higher 
than in controls. 
Conclusion 
In this series, which represents the largest experience with 
adjuvant bone marrow infusion in pancreas recipients, there 
was a higher steroid withdrawal rate (p = 0.02), fewer rejec-
tion episodes, and no pancreas graft loss after 3 months in 
bone marrow recipients compared with contemporaneous 
controls. All pancreas allografts lost to chronic rejection (n = 
6) were in the non-bone marrow group. Donor bone marrow 
administered around the time of surgery may have a protec-
tive effect in pancreas transplantation. 
tion in the surgical complication rate.3.4 and improvement in 
quality of life. 5.6 In addition. there is emerging evidence that 
the secondary complications of diabetes can be stabilized 
and even reversed with prolonged normal carbohydrate me-
tabolism. 7- 9 The principal reasons for the improved long-
term success have been both the increasing experience with 
tacrolimus-based immunosuppression and the reduction in 
surgical complications. in part associated with the reintro-
duction of primary enteric drainage of the exocrine secre-
tions. IO· 11 Complications associated with duodenocystos-
tomy. the most common method of exocrine drainage. have 
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Table 1. RECIPIENT DEMOGRAPHICS 
Bone No Bone 
AIISPK Marrow Marrow 
(n = 151) (n = 53) (n = 98) 
Age (yrs) 
Mean:t SO 40.2:t 7 39.8 :t 8.6 40.0 :t 6.9 
Range 27.6--57 27.6--56.1 28.8-57 
Sex 
Male 53% 51% 56% 
Female 47% 49% 44% 
Race 
African American 7% 10% 4% 
White 93% 90% 96% 
PRA(%:t SO) 3:!: 7.5 2.7:!: 4.7 3.2 :t 8.6 
Drainage 
Enteric 88% 85% 90% 
Bladder 12% 15% 10% 
Pretransplant dialysis 
None 35% 30% 37% 
Peritoneal 23% 24% 22% 
Hemodialysis 42% 46% 41% 
PRA. panel reactive antibody; SPK. simultaneous pancreas/kidney transplant. 
included fistula, urinary tract infection and sepsis, and met-
abolic acidosis, and have required conversion to enteric 
drainage in 25% of pancreas recipients. I 
Despite these improving outcomes, graft loss to rejection 
still occurs in close to 10% of patients. as reported by 
Sollinger et al in an excellent large series of combined 
pancreaslkidney recipients. 1 If a significant reduction in 
rejection-related graft loss could be achieved. even more 
patients would benefit from the procedure. 
The tolerance induction model. using adjuvant perioper-
ative donor-specific bone marrow. was based on the obser-
Table 2. DONOR DEMOGRAPHICS 
Bone No Bone 
A1ISPK Marrow Marrow 
(n = 151) (n = 53) (n = 98) 
Age (yrs) 
Mean:!: SO 30.2 :t 13.6 27.6:!: 12.8 31.6:t 13.8 
Range 6.8-61.4 10.9-55.5 6.8-61.4 
Sex 
Male 51% 60% 45% 
Female 49% 40% 55% 
Race 
White 85% 84% 86% 
African American 8% 7% 9% 
Other 6% 9% 5% 
Mean cold ischemia 
time:!: SO (hrs) 
Kidney 16.3 :!: 4.6 15.8:!: 5 16.5 :!: 4 
Pancreas 17.7::: 4 17.5 :!: 4 18:!: 3.8 
SPK. simultaneous pancreaS/kIdney transplant. 
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Antigens 
Matched 
0 
2 
3 
4 
5 
6 
Table 3. HISTOCOMPATIBILITY 
MATCHING 
Bone Marrow No Bone Marrow 
(n = 53) (n = 98) 
25% 30% 
42% 32% 
24% 24% 
5% 8% 
4% 5% 
1% 
vation by Starzl et al that donor leukocytes were found in 
organs and tissues of long-term surviving transplant recip-
ients. 12 This microchimeric state. found many years after 
transplantation in successfully transplanted patients, some 
of whom were no longer receiving immunosuppression. 
suggested a favorable balance of the natural host-versus-
graft and graft-versus-host reactions. Several reports since 
have confirmed an augmentation of chimerism in trans-
planted recipients who were simultaneously given donor 
bone marrow infusions. 13•14 This report will describe in 
detail. for the first time. our observations in a series of 
simultaneous pancreaslkidney transplant recipients. trans-
planted between July 1994 and January 1999. who either 
received or did not receive perioperative donor bone mar-
row, mainly as a function of the donor family's giving 
permission for removal of the vertebral bodies. 
MATERIALS AND METHODS 
Recipient Selection and Demographics 
Recipients were evaluated by a transplant surgeon, a 
transplant internist, a nurse transplant coordinator. and other 
members of the health care team. All patients had type I 
diabetes and ranged in age from 27.6 to 57 years. All 
patients underwent a dobutamine echocardiogram or an 
adenosine thallium scan. which was reviewed by a cardiol-
ogist to seek evidence of ischemia and to determine whether 
a cardiac catheterization was needed. If a potentially cor-
rectable lesion appeared on cardiac catheterization, inter-
vention was carried out before listing the patient for trans-
plantation. A few patients with uncorrectable and critical 
coronary disease were not listed because the risk was 
thought to outweigh the benefit. No other exclusion criteria 
were used. including amputations. blindness. or age older 
than 55. Demographics showed a nearly equal percentage of 
characteristics in the bone marrow and non-bone marrow 
groups (Table I). 
Donor Selection and Characteristics 
All donors younger than age 65 were considered. Ages 
ranged from 6.8 to 61.4 years, with a mean age of 30.3 
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Figure 1. Overall patient. kidney. and pancreas allograft survival for 
151 consecutive simultaneous pancreas/kidney transplants. 
years. Donors with a history of cardiac arrest, two or more 
vasopressors. or hemodynamic instability were not ex-
cluded unless there was evidence of progressive renal dys-
function or pancreatic ischemia with a rising serum lipase 
determination. 
Acceptance criteria and data regarding the use of "high-
risk" donors were described in a recent report. 15 The results 
of these high-risk donor pancreases, once transplanted, were 
not different from the overall results, provided that the 
organs were carefully selected based on the extent of fatty 
infiltration and fibrosis and the adequacy of the back-table 
flush with University of Wisconsin solution (Viospan, Du-
Pont, Wilmington, DE). Donor demographics are detailed in 
Table 2. Histocompatibility matching is shown in Table 3. 
The donor operation was a rapid en bloc liver and pan-
creas removal with separation of the two organs at the donor 
hospital; the technical details have been reported earlier. 16 
The rapid en bloc technique was applicable for hemody-
namically unstable donors and donors without a heart beat 
as well as stable donors. 
The final selection of an organ from a high-risk donor 
was based on careful inspection of the pancreas at the time 
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Figure 2. Pancreas allograft survival. comparing adjuvant bone mar-
row (8M) vs. no 8M. 
of back-table preparation, particularly with regard to the 
appearance of the pancreatic parenchyma; the quality of the 
vessels, including the Y graft; and the rate of venous efflu-
ent at the time of back-table flush. 
Transplant Procedure 
The kidney transplant was usually performed first. Kid-
neys were placed in a retroperitoneal position on the left 
side through a lower abdominal oblique incision, which was 
closed before the pancreas procedure was started. 
The pancreas was transplanted through a separate right 
lower quadrant intraperitoneal oblique incision. During the 
kidney transplant procedure, or before both procedures, the 
bench work on the pancreas was performed. This included 
individual ligation of the mesenteric vessels at the root of 
the mesentery, shortening of the duodenum to a 7- to lO-cm 
segment, ligation of the common bile duct, and joining of 
the donor iliac Y graft to the splenic and superior mesenteric 
arteries. The donor common iliac vein graft was used on 
several occasions to lengthen the portal vein, if it had been 
Table 4. CAUSES OF PANCREAS FAILURES IN 151 SPK PATIENTS 
Mean Survival in Days 
No. Causes (Rangel BM NoBM p Value 
1 Thrombosis (n = 8) 1 (0-2) 2 6 NS 
2 Pancreatitis (n = 7) 11 (7-21) 5 2 NS 
3 Rejection (n = 7) 342 (12-729) 7 0.03 
4 Death (n = 2) 373 (92--655) 2 NS 
5 SepsIs (n = 2) 58 (21-96) NS 
6 Unknown (n = 1) 1295 NS 
SPK. Simultaneous pancreaS/kidney transplant: 8M. bone marrow. 
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Figure 3. Kidney allograft survival, comparing adjuvant bone marrow 
(BM) VS. no BM. 
divided near the junction of the splenic vein and the superior 
mesenteric vein. 
The transplant procedure was performed by suturing the 
portal vein. with or without an extension graft. to either the 
external or common iliac vein and the donor Y graft com-
mon iliac artery to the recipient external. common. or in-
ternal iliac artery. depending on the positioning of the organ 
and the quality of the recipient vessels. The end of the 
duodenum was joined to the side of the proximal jejunum in 
a standard two-layer anastomosis, With the bladder-drain-
age technique. the organ was placed lower on the iliac 
vessels and a two-layer side-to-side duodenocystostomy 
was performed. 17 
Immunosuppression 
From the beginning of the program in July 1994, the 
immunosuppressive protocol consisted of a triple-drug reg-
imen based on tacrolimus. A loading dose of oral tacroli-
mus. 0.15 mg/kg. was given on admission before transplan-
tation. and 500 mg intravenous methylprednisolone was 
administered during surgery after induction of anesthesia. 
After surgery, the patients were maintained on intravenous 
tacrolimus at a constant infusion for 4 to 7 days to maintain 
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Figure 4. Pancreas allograft survival with azathioprine VS. mycophe-
nolate as a third immunosuppressive agent. 
whole blood levels of 20 to 25 ng/ml for the first 2 weeks. 
Once the patients could tolerate a diet. they were converted 
to oral tacrolimus to maintain target whole blood trough 
levels of 15 to 20 ng/ml by I month. 10 to 15 ng/ml by 3 
months, and 5 to 12 ng/ml chronically. Mycophenolate 
mofetil. I g twice a day, was given after surgery, with a dose 
reduction if the drug was not tolerated because of diarrhea 
or other gastrointestinal tract symptoms. Only a few patients 
were converted to azathioprine. All patients received taper-
ing steroid doses after surgery, starting at 200 mg/day and 
reduced by 40 mg/day to 20 mg/day by day 6. If tolerated. 
prednisone was slowly tapered over the first 2 years. with 
discontinuation of the drug in >60% of patients. 
Rejection was treated with steroids in all cases, either 
intravenous methylprednisolone boluses for 3 days or a 
single methylprednisolone bolus followed by the steroid 
recycle. as described above. A few patients received anti-
lymphocyte therapy if the rejections were not responsive to 
steroids. The first 50 patients received azathioprine at 1.5 to 
2 mg/kg at the beginning of the program. before mycophe-
nolate was available. Only three patients were converted 
Table 5. CAUSES OF KIDNEY FAILURE IN 151 SPK PATIENTS 
Mean Survival in Days 
No. Causes 
Rejection 
2 Death (n = 4) 
3 SepsIs (n = 2) 
4 ThrombOSIS (n = 1) 
. losses to relectlon al 14.6 and 42 months aner transplanlatlon 
SPK. Simultaneous pancreaS/kidney transplant: 8M, bone marrow. 
(Range) 
609 (12-1291) 
509 (92-739) 
58 (21-96) 
21 
BM NoBM p Value 
2" 6 NS 
3 NS 
2 NS 
NS 
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Figure 5. Kidney allograft survival with azathioprine vs. mycophenolate 
as a third immunosuppressive agent. 
from tacrolimus to cyclosporine because of persistent hy-
perglycemia that did not respond to dose reduction. 
Isolation and Infusion of Donor Bone 
Marrow With In Vitro MonitOring 
Bone marrow cells were harvested from the vertebral 
bodies of the cadaveric donors by a method described 
previously. III In patients receiving perioperative donor bone 
marrow after organ revascularization. 3 to 6 X l all unmod-
ified cells per kilogram was infused through a central intra-
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Figure 6. Panoreas allograft survIVal in simultaneous pancreaS/kidney 
tranSPlants. comparing bladder vs. enteric drainage. 
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Figure 7. Cumulative risk of rejection in simultaneous pancreas/kidney 
transplants, comparing adjuvant bone marrow (8M) vs. no 8M admin· 
istration. 
venous line, Using a quantitative method of nested poly-
merase chain reaction,I9 the presence of donor cell 
chimerism was serially determined in the peripheral blood 
of both the study and control patients. 
Statistical Methods 
Data were recorded as mean ::!:: SD. Time-dependent 
variables-allograft failure and death-were estimated by 
Kaplan-Meier survival analysis. Comparison of rate of re-
jection in the bone marrow versus non-bone marrow groups 
was performed by log-rank analysis. Comparison of means 
between independent groups of continuous variables was 
estimated by independent sample t test. Pearson chi square 
test or Fisher's exact test when appropriate was done for 
categorical data. Probability values <0.05 were considered 
significant. 
Ethical Considerations 
All subjects reported in this manuscript were thoroughly 
informed at the time of the transplant evaluation about the 
Table 6 • REJECTION ANALYSIS· 
No. of Rejection BM NoBM 
Episodes (n = 53) (n = 98) P Value 
None 23 (43%) 21 (21%) 0.05 
One 18(34%) 34 (34%) NS 
Two or more 12(22%) 43(44%) 0.05 
Mean 0.94:!: 1.1 1.57:!: 1.3 0.003 
• Cox regression analvsls for proponlonal hazara assumption BM VS. no BM. 
hazara at 0.59 (p = 0.017) 
8M. bone marrow. 
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Table 7. PERCENTAGE OF PATIENTS 
STEROID-FREE 
Steroid-Free 
Year 1 
Year 2 
Year 3 
BM, bone marrow. 
BM 
22% 
45% 
67% 
NoBM 
19% 
38% 
45% 
p Value 
NS 
NS 
0.02 
bone marrow augmentation study, in accord with the ethical 
standards of the Internal Review Board of the University of 
Pittsburgh. and gave their written consent before the trans-
plant procedure. 
RESULTS 
The overall patient. kidney, and pancreas actuarial sur-
vival rates in 151 patients are shown in Figure I. with 3-year 
actuarial survival rates of 95%, 87%. and 80%, respectively. 
Figure 2 shows the pancreas Kaplan-Meier survival curves: 
no pancreases were lost after 3 months in recipients who 
received simultaneous donor bone marrow. whereas seven 
pancreases were lost to rejection in patients who did not 
receive donor bone marrow. Six of these seven grafts were 
lost between 6.7 and 25.5 months, whereas one was rejected 
early because of a humoral rejection in a highly sensitized 
patient in whom cytotoxic antibodies developed after sur-
gery (Table 4). The non-rejection-related causes of pancreas 
loss in the two groups were not statistically different (see 
Table 4). Kaplan-Meier curves of kidney survival show an 
equal loss rate in both groups (Fig. 3). However. six of the 
eight kidney losses to rejection between I and 3.5 years 
were in the non-bone marrow group (Table 5). 
The bone marrow and non-bone marrow groups were 
compared with reference to mycophenolate versus azathio-
prine use. and there was no difference in either pancreas or 
kidney survival (Figs. 4- and 5. respectively). Similarly. 
Figure 6 compares the pancreas survival curves according to 
the method of exocrine drainage: there was no difference, 
although only 19 of the 151 patients were bladder-drained. 
The cumulative risk of rejection. comparing the bone 
marrow group with the non-bone marrow group. shows a 
striking difference (Fig. 7). The increase in the number of 
rejection episodes. including multiple rejections. in the non-
bone marrow group compared with the bone marrow group 
is shown in Table 6. Forty-three percent of the bone marrow 
group but only 21 % of the non-bone marrow group was 
rejection-free (p = 0.05). Further. twice as many patients in 
the non-bone marrow group had two or more rejections 
compared with the bone marrow recipients. and the number 
of rejections per patient was greater in the non-bone marrow 
group (p = 0.03. see Table 6). 
Steroid withdrawal was more common in the bone mar-
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row group at 3 years after transplantation (p = 0.02, Table 
7). Patients were withdrawn from steroids based on their 
immunologic status. The non-bone marrow recipients had a 
mean tacrolimus level greater than that in the bone marrow 
group (p = 0.009); this is not surprising. given that more 
rejection episodes occurred in the non-bone marrow group 
(Table 8). Further. the bone marrow patients appeared to 
have better pancreatic graft function. as reflected by a lower 
glycosylated hemoglobin value (p = 0.02, see Table 8). 
Causes of death in seven patients included four cardiac-
related, two sepsis, and one posttransplant lymphoprolifera-
tive disorder (PTLD; Table 9). The patient in the bone 
marrow group with posttransplant lymphoproliferative dis-
ease died with normal pancreatic and renal function. This 
patient was seronegative for Epstein-Barr virus, and the 
donor was seropositive. One patient in each group died from 
sepsis. 
Bone marrow patients had a significantly greater (92%) 
incidence of chimerism in their peripheral blood compared 
with the controls (70%). This finding was consistent over 
the course of serial follow-up. Similarly, using semiquanti-
tative polymerase chain reaction, the levels of donor cell 
chimerism were found to be at least two logs higher in the 
majority of the evaluated (male/female transplant recipi-
ents) bone marrow patients compared with the controls. 
DISCUSSION 
Results of pancreatic transplantation have improved 
steadily in the past 5 years. 2 Tacrolimus-based immunosup-
pression has played a substantial role in this improvement, 
which was recently reported by Gruessner20 in a retrospec-
tive multicenter analysis. Our center began using tacrolimus 
from the inception of the program. and results, even in the 
early phase of the program. were far better than with con-
ventional drug regimens. 21 The surveillance strategy, in 
terms of frequency of fine-needle aspiration biopsies of both 
organs22 and core kidney biopsies. resulted in the diagnosis 
of rejection with minimal. if any, abnormal laboratory find-
ings. Further. appropriate use of tacrolimus. with high up-
front dosing in the first few weeks. reduced the vigor of 
acute rejections in most cases and obviated the requirement 
Table 8. LABORATORY VALUES AT 
RECENT FOLLOW-UP 
Bone Marrow No Bone Marrow 
(Mean:!: SO) (Mean:!: SO) p Value 
T acrollmus (ng/mll 8.9 = 2.6 10.9 = 4.7 0.009 
Hemoglobin A'e 5.07 = 0.8 6.1 = 1.8 0.02 
Creatinine (mg%) 1.3 = 0.4 1.5:!: 0.7 NS 
Glucose (mg%) 96 = 27 96 = 25 NS 
Amylase (u/l) 68 = 37 75:!: 62 NS 
lipase (u/l) 113=109 127 = 188 NS 
1 
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Table 9. CAUSES OF DEATH IN 151 SPK PATIENTS 
No. Causes 
'1 Lymphoma 
2 Sepsis 
3 Cardiac 
4 Sepsis 
5 Cardiac 
6 Cardiac 
7 Cardiac 
, EBV -seropositive donor to seronegative recipient. 
SPK. simultaneous pancreas/kidney transplant. 
Time (mo) 
3.0 
5.7 
18.4 
21.8 
24.6 
38.4 
44.5 
for antilymphocyte induction_ Although we were initially 
apprehensive regarding tacrolimus because of its reported 
hyperglycemic effect,23 when this did occur in a few pa-
tients. it was only transient and disappeared with reduction 
in the dose of tacrolimus and steroids. The long-term effect 
of tacrolimus on glucose metabolism. analyzed by Jordan et 
al.24 showed no deleterious effect in terms of abnormal 
fasting blood sugar values and glycosylated hemoglobin 
values. 
Cytomegalovirus disease occurred in only one patient in 
this series, although the cytomegalovirus antigenemia 
(pp65) test was positive in 19 patients who were seronega-
tive at the time of transplantation from a seropositive donor. 
The recipients who turned positive for cytomegalovirus 
antigenemia were treated preemptively with ganciclovir for 
14 days, or until the antigenemia disappeared. The relative 
absence of cytomegaloviral disease was possibly a byprod-
uct of avoiding antibody induction therapy. 
Although we introduced the current method of bladder 
drainage more than a decade ago. 17 we have returned to a 
modification of our original technique of enteric drain-
age:25.:26 to avoid the surgical complications related to blad-
der drainage. We performed 18 bladder-drained procedures 
in this series and reserved the bladder-drainage procedure 
for solitary pancreas transplants or pancreas after kidney 
transplants: the urinary amylase levels are useful in moni-
toring for rejection because the kidney cannot be used as a 
marker. In addition. we used bladder drainage when the 
graft is placed in the left iliac fossa to avoid performing the 
enteric anastomosis above the sigmoid colon or through its 
mesocolon. It is encouraging that only 2/37 (6%) bladder-
drained cases in our overall series of 177 patients required 
conversion to enteric drainage. 
Although rejection of the allografted pancreas does occur 
in the bone marrow recipients. there were fewer episodes: 
more patients had no detectable rejection: more patients 
were weaned off steroids: better graft function existed. as 
measured by a lower glycosylated hemoglobin value: there 
was no pancreas loss to rejection after 3 months compared 
Graft Function 
Bone Marrow Pancreas Kidney 
Yes Yes Yes 
Yes No No 
No No Yes 
Yes Yes Yes 
Yes No Yes 
No No No 
Yes No No 
with six late rejection-related losses in the non-bone marrow 
recipients; and tacrolimus blood levels were lower. 
The higher level of donor cell chimerism in the bone 
marrow recipients suggests that bone marrow administra-
tion augments the naturally occurring chimerism, which 
may shift the bidirectional immune responses to strengthen 
the graft-versus-host arm. Donor leukocytes have been 
shown to migrate to other organs and tissues in recipients 
after transplantation.27 These donor stem and dendritic cells 
continue to be immunologically active. Perhaps a partial 
tolerance is induced by clonal deletion or exhaustion, the 
phenomenon that occurs when T cells are presented in a 
setting of excessive antigen, such as a pancreaslkidney/ 
duodenal organ transplant composed of lymphoid tissue in 
the duodenum and root of the mesentery. Immunosuppres-
sion is needed. particularly at the beginning, to establish 
engraftment and allow the bidirectional immunologic pro-
cess to establish itself. 
We reported a similar phenomenon in the fully allogeneic 
rat model with a pancreas/spleen transplant where the pan-
creas was accepted for the lifetime of the rat, provided that 
a short course of immunosuppression was administered at 
the outset.28 The same transplant experiment without trans-
planting the spleen. a virtual factory of pluripotent cells as 
well as other mature T cells. resulted in graft loss to rejec-
tion in all cases despite the same course of immunosuppres-
sion. Although our previous experience with pancreatic and 
splenic transplantation in humans resulted in severe graft-
\'ersus-host disease.25.26 the permanent tolerance achieved 
in this allogeneic rat model suggests that there is a favorable 
bidirectional immune response. 
In summary. bone marrow augmentation. in this clinical 
model. seemed to produce a beneficial effect from an im-
munologic point of view. at least in terms of reducing the 
incidence of rejection and late graft loss to rejection. In 
addition. these data suggest that tacrolimus-based immuno-
suppression without antilymphocyte induction is highly ef-
fective. Enteric drainage of the exocrine secretions appears 
to be an appropriate and perhaps preferable technique. In the 
--- -------_ .. _-._--------
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future, more effective methods of achieving prolonged graft 
acceptance should be pursued. employing strategies to po-
tentiate the beneficial effect of bone marrow augmentation 
on chimerism and graft acceptance. 
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Discussion 
DR. DAVID E.R. SUTHERLAND (Minneapolis. Minnesota): Dr. 
Corry. your overall results in simultaneous kidney/pancreas recip-
ients since 1994 are very good. with 3-year kidney and pancreas 
graft survival rates of over 90% and 80%. respectively. 
Despite your disclaimer. it seems that the chronic rejection rate 
is almost the same in the two groups. with and without donor bone 
marrow. The main effect of bone marrow was on the acute rejec-
tion episode rate. Most rejection episodes occurred in the first 6 
months, and there was a 20% difference at that time point. There-
after. the curves remained parallel. The chronic rejection rate 
seemed to be low in both groups and I would like you to comment 
on that. 
How did you diagnose the rejection episodes? At the University 
of Minnesota. we have used a more or less constant protocol since 
1994. without bone marrow. giving antithymocyte globulin (ATG) 
for induction with Prograf (tacrolimus). CellCept. and prednisone 
for maintenance immunosuppression. We recently analyzed our 
results from 1994-1998 and the rejection episode rates in the 
simultaneous pancreaslkidney (SPK) and the pancreas after kidney 
(PAK) groups were 25% at 6 months in both. much lower than 
what you reported even in your bone marrow group. So it is 
possible that the A TG is more effective at reducing the incidence 
of rejection episodes than bone marrow. On the other hand. what 
proportion of your rejection episodes were diagnosed solely by 
biopsy and were not apparent on clinical grounds? 
Also. did you differentiate the rejection episodes diagnosed in 
the pancreas or the kidney" Do you do protocol biopsies in both 
the pancreas and kidney. or just the kidney? 
Pancreas transplants alone are being done at increasing num-
bers. and this is where the future of pancreas transplantation lies. 
but there is still a higher rejection episode rate. When we analyze 
our data from 1994- I 998. the same protocols that resulted in only 
a 25% rejection episode rate by 6 months in the SPK and PAK 
groups were associated with a 6OC/c rejet:tion episode rate in the 
pancreas transplant alone group. in spite of using ATG. It seems 
that the PTA group may he the one that would have the most 
benefit from the addition of the bone marrow. Finally. on theoret-
• 
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ical groups we might have expected bone marrow to increase the 
early rejection episode rate because of the large load of passenger 
leukocytes directly stimulating the recipients' immune system, 
Later. when the bimodality of graft versus host and host versus 
graft balance occur. the benefit of bone marrow would be seen 
long-term. Yet it seems just the opposite. I would like your 
comments on this paradox. 
PRESENTER DR. ROBERT J. CORRY (Pittsburgh, Pennsylvania): I 
think as I showed in the two slides there was no rejection in the 
bone marrow group after 3 months, either chronic or acute. The 
seven losses occurred in the non-bone marrow group from 4 
months to 3 years, so I think there is some protection against 
chronic rejection in the bone marrow patients. 
Now, the diagnosis of rejection is an important point. A lot of 
these rejections were based on protocol biopsy without any clinical 
or laboratory findings, and "borderline" rejection was treated. 
Therefore, we are not necessarily basing the diagnosis of rejection 
solely on clinical or laboratory grounds. The pancreas-only group. 
I agree. would be a good group to try the bone marrow on, since 
those patients seem to have an increased rejection rate. 
DR. CLYDE F. BARKER (Philadelphia. Pennsylvania): Dr. Corry 
has presented a series of pancreas transplants today with remark-
ably tine results. I think it is appropriate to say that Dr. Corry is 
one of a very small group of investigators, including David Suth-
erland and just a few others, who are responsible for bringing 
pancreatic transplantation to its present level. As he said, it should 
no longer be considered an experimental procedure. Considering 
that only a few years ago, pancreas transplants could be expected 
to have no better than a 30% to 40% I-year graft survival while the 
success of kidney transplants was about twice that good, it is quite 
amazing that Dr. Corry is now able to report almost 90% I-year 
graft survival. 
Ironically, Dr. Corry's overall results are so good that it is 
almost impossible to distinguish the outcome of his experimental 
(bone marrow-treated) group from that of the control (non-bone 
marrow-treated) patients. Patient pancreas and kidney survival at I 
and 3 years are virtually the same in both groups. 
However. the difference in incidence of rejection episodes in the 
two groups is quite impressive. Rejection episodes were 50% more 
common in the non-bone marrow group than in the bone marrow-
treated patients. Even more suggestive that bone marrow helps is 
that none of the pancreas grafts in bone marrow-treated patients 
were lost to rejection after 3 months. while seven in the control 
group were rejected. 
It is important also, that by 3 years posttransplant, Dr. Corry 
succeeded in completely withdrawing steroids in 67% of the bone 
marrow-treated patients. However. I would like to ask him whether 
in a given patient he is able to decide with certainty whether 
steroids can be withdrawn and if so when? Is it possible that in the 
control patients <those not treated with bone marrow) some of the 
seven graft losses could have been avoided by not withdrawing the 
'iteroids. since in that group 45'70 were withdrawn from steroids? 
Dr. Corry. do you have sufficient confidence in the bone marrow 
treatment that immunosuppression might be withdrawn com-
pletely') Dr. Starzl has in the past suggested this possibility. I 
wonder if Dr. Corry is considering this with his pancreas transplant 
patients. 
That treatment of allograft recipients with donor bone marrow 
would have a beneficial impact on outcome certamly makes sense. 
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Long before Dr. Starzl made the important observation of persis-
tent microchimerism in his long-term human survivors of renal and 
hepatic allografts, studies done by Billingham. Brent, and Me-
dawar in neonatal mice, and by Tony Monaco in adult mice, 
indicated that chimerism promoted by administration of donor 
bone marrow transfusion led to tolerance of subsequent tissue 
allografts from the same donor. 
Another aspect of Dr. Corry's study is particularly intriguing. 
This interests me because of our own recent studies by Drs. 
Uchikoski and Naji in our laboratories at the University of Penn-
sylvania in an animal model of autoimmune diabetes. the BB rat. 
In these animals, the chimerism resulting from pancreaticoduode-
nal transplantation alone (without bone marrow augmentation) is 
quite substantial. This chimerism has a beneficial effect on graft 
survival but this is ablated by pretransplant irradiation of the graft 
to get rid of the passenger leukocytes. 
This protective influence interestingly is even more effective in 
preventing autoimmune damage to the transplanted islets than it is 
in preventing allogeneic rejection. Since several recent reports 
indicate that human islet and pancreatic transplants are susceptible 
to damage by autoimmunity as well as rejection, I wonder if Dr. 
Corry has considered the possibility that some of his grafts have 
been damaged by autoimmunity rather than by rejection. and 
whether the bone marrow may be helpful in preventing autoim-
mune damage. Graft biopsies might provide some insight to this 
question. 
This study is a very good one. I congratulate Dr. Corry on his 
excellent results. 
DR. CORRY: I think that you have made a very important point 
that perhaps we should be a little bit more conservative in with-
drawing steroids from the non-bone marrow group. I don't know 
whether the seven losses from the bone marrow group had steroid 
withdrawal earlier. but I will have to look that up and I will let you 
know. 
I don't know whether I would at this point remove immunosup-
pression totally. We have several patients who are out 3 years just 
on tacrolimus alone. That strategy has been tried by John Fung's 
group in the patients who have long-term surviving livers, and I 
think they have had some success with that. 
I can't really answer the autoimmunity question. I am aware of 
your rat study. We did have an earlier rat study that you may be 
aware of where we did the pancreas/spleen transplant. Providing 
we abrogated GVH. we got long-term survival for the lifetime of 
the rat just by the addition of the spleen. But I really can't answer 
the autoimmunity problem in the biopsies. I don't think it existed, 
however. 
DR. DONALD C. DAFOE (Palo Alto. California): Dr. Corry, I 
would like to add my congratulations to the other discussants' for 
your excellent series of pancreas transplants and this innovative 
clinical trial of donor bone marrow infusion. And thank you for the 
opportunity to review your manuscript. The patient graft survival 
[hat was presented in a difficult group of patients with end-stage 
diabetic nephropathy is a tribute to the experience of Dr. Corry and 
his group-careful recipient and donor selection. and certainly 
better immunosuppression. 
As acute rejection is brought under control with our current 
combinations of new drugs. noting that most organ recipients do 
not experience acute rejection now, the focus must shift to the 
problems of chronic immunosuppression-associated insidious side 
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effects as well as chronic rejection. Although I-year graft survivals 
of 85% have been achieved, the chronic graft loss rate presents a 
curve that runs parallel to that of a decade ago due to chronic 
rejection. 
The concept of chimerism, which simplistically is often envi-
sioned as a dynamic equipoise between rejection and GVH (graft 
versus host), has been championed by Dr. Starzl, Miami, and the 
Alabama group as the approach to induce tolerance. Your study 
supports an association between donor bone marrow infusion and 
allograft acceptance, and it is a promising start. I have a number of 
questions. 
This is not a randomized study, and as we all know, biases do 
creep in. The withdrawal of steroids in the donor bone marrow 
group may be more aggressive or follow-up may be more vigor-
ous, leading to a self-fulfilling prophecy. My question is, do you 
plan randomization? 
You mentioned in your manuscript that PCR for chimeric cells 
was carried out. I did not see those data. And I would like to ask 
about the percentage of donor cells in the periphery and whether 
you sampled other compartments such as the host bone marrow or 
the graft itself. 
There are multiple variables in this kind of triaL the dose of the 
bone marrow. the timing, the cell type infused, and whether a 
depletive regimen is used. What strikes me is that we need better 
endpoints rather than patient and graft survival. 
DR. CORRY: I will try to answer those quickly. The randomiza-
tion was not done except by the willingness of the donor family to 
give permission for removal of vertebral bodies. When that was 
done, the recipients received the marrow. When it was not done, 
they didn't receive the marrow. So that was the only randomiza-
tion. The patients were made aware of this study on evaluation and 
signed a permit. 
We didn't always remember who got bone marrow and who 
didn't. We didn't know that until we looked up this data. We did 
not sample the bone marrow or the organs in the recipients of 
long-term surviving grafts. 
Regarding the chimerism data, I will try to get that for you when 
I discuss a portion of this topic at the ASTS meeting. It was 
essentially two logs higher in the bone marrow than in the non-
bone marrow group. There was chimerism in the non-bone marrow 
group, but not as high a level. 
DR. GEORGE E. PIERCE (Kansas City, Kansas): I also compliment 
Dr. Corry for this important and interesting paper. Bone marrow 
can markedly prolong allograft survival in a number of different 
experimental models but it has been very difficult to demonstrate 
this benefit in humans. This is not surprising since. as Dr. Barker 
has indicated. the results at I year and even 3 years are so good 
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with conventional immunosuppression. it would be difficult to 
detect a small incremental benefit due to the bone marrow. 
In fact, in your study, Dr. Corry, the I-year and 3-year pancreas 
and kidney graft survival rates. as Dr. Barker has indicated, are 
very similar for the two groups. So the evidence that bone marrow 
is of benefit in your patients rests largely upon the significant 
difference in rejection rates. But the definition of rejection is 
somewhat arbitrary, and the diagnosis of rejection can be quite 
subjective. So I wonder if you could elaborate a little bit more on 
your diagnosis of rejection. Was it based solely on histologic 
criteria? Did you use any functional criteria or a combination of 
criteria to make the diagnosis of rejection? 
With longer follow-up, this may not be a critical point because. 
as we will hear tomorrow from the Minnesota group, it appears 
that the best predictor of chronic rejection is acute rejection. i.e., 
acute rejection is the best predictor of long-term graft loss. So 
perhaps with longer follow-up--that is, 5 years and beyond-we 
may see a more clear-cut benefit in the group that received bone 
marrow. if indeed. as you suggest. bone marrow decreased the 
incidence of acute rejection. 
I would like you to comment further on Dr. Starzl's interesting 
hypothesis that attempts to explain long-term graft acceptance on 
the basis of balanced graft versus host and host versus graft 
reactions. I am especially interested if you have any insight into the 
nature of the intriguing graft versus host component of this two-
way mechanism. 
I appreciate the opportunity to discuss this important paper. 
DR. CORRY: I agree with everything you said. 
The diagnosis of rejection was not based solely on clinical or 
laboratory findings. There were protocol fine-needle biopsies of 
both organs. the kidney and the pancreas. in the first 2 years. and 
there were protocol biopsies of the kidney at various times. We had 
rejection diagnosed with creatinines at 1.0 when the lipase was 
rising a little bit and we biopsied the kidney and showed rejection. 
With regard to the two-way paradigm, I would have to refer you 
to the article by Starzl and Zinkemagle. In a 1990 paper. we 
discussed this concept in a rat model where we mentioned this 
bidirectional response, where there was GVH on the one hand in 
the rat spleen model and rejection on the other. Providing we were 
able to eliminate clinical GVH. this dual immune response resulted 
in survival for the lifetime of the animal. which did not occur if 
you didn't put the spleen in. which is a source of many pluripotent 
stem cells. I would refer you to that paper and the paper by Starzl 
and Zinkemagle and some of the others that Starzl has written, 
particularly the New Englalld Journal Christmas Eve 1998 Review 
article. 
I would like to thank all the discussants for their remarks. 
